Previsión
El precio objetivo medio de los analistas es de 54,08 € (+89,42 %). La mediana es de 55,60 € (+94,75 %).
| Comprar |
14 |
| Mantener |
0 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Pharvaris presents Deucrictibant ahead of market launch after strong phase‑III data
Pharvaris unveiled final plans for Deucrictibant at the Morgan Stanley Healthcare Conference. The oral HAE drug showed Phase‑III efficacy of 87% in HAE types 1 and 2 (83% in the extended population). The company is targeting U.S. approval for on‑demand treatment with a PDUFA target date of April 2027 and is preparing a prophylactic indication thereafter. Management highlighted a favorable safety profile versus competing oral therapies, plans to build a commercial organization (target: ~90 employees) and expects liquidity into mid‑2028 in the base case. Additional data from CREATE and an open‑label extension study are expected to be released in the coming months. » Más en de.investing.com
Pharvaris shows phase‑III success: Deucrictibant reduces HAE attacks by 87%
At the Cantor Fitzgerald conference Pharvaris presented phase‑III data (CHAPTER‑3) showing an 87% reduction in hereditary angioedema attacks with the oral B2‑receptor antagonist Deucrictibant. The study included patients from six continents and used an extended‑release formulation that may explain the improved efficacy profile. Safety questions remain: two grade‑3 elevations in liver enzymes and one serious laryngeal event were reported, though the company considers the overall profile comparable to existing prophylactics. Pharvaris plans to launch the on‑demand treatment on April 8, 2025, and aims to file for approval for prophylaxis in the first half of 2025, supported by a targeted commercial platform for bradykinin‑mediated angioedemas. » Más en de.investing.com
Pharvaris: oral HAE drug deucrictibant shows strong phase‑III data
Deucrictibant reduced HAE attacks by 87% in the phase‑III prophylaxis study in type‑1/ type‑2 patients (83% in the overall population) and replicated earlier results in a larger, global cohort. Pharvaris expects a PDUFA date for the on‑demand formulation on April 23 and plans to submit the regulatory application for the prophylaxis version in H1 2025. Two cases of elevated liver enzymes were reported but, according to management, are comparable to known risks; long‑term safety is being investigated in the open‑label extension study CHAPTER‑4. Commercially, the company intends to target treatment‑naive patients as well as users of ORLADEYO and injectable therapies. » Más en de.investing.com
Pharvaris rises sharply after positive phase‑3 data for HAE drug
Pharvaris reported statistically significant topline results from the pivotal phase‑3 study CHAPTER‑3: Deucrictibant XR reduced the mean monthly HAE attack rate by 83% versus placebo (p<0.0001) and lowered the rate in HAE type 1/2 by 87%. All secondary endpoints were significant and the safety profile proved well tolerated. The company intends to use the data for regulatory submissions, including a New Drug Application in the US in the first half of 2027, and the stock then reached a new 52‑week high. » Más en de.investing.com
Pharvaris: Phase‑3 study of Deucrictibant XR meets primary endpoint and markedly reduces HAE attacks
Pharvaris reports that the Phase‑3 CHAPTER‑3 study of Deucrictibant XR met its primary endpoint for prevention of hereditary angioedema (HAE) attacks. A once‑daily 40 mg dose reduced the mean monthly attack rate across all three HAE types by 83% versus placebo and by 87% in HAE types 1 and 2; all secondary endpoints were also statistically significant. Protection began in the first week of treatment and was maintained over 24 weeks. Deucrictibant XR was well tolerated, with no treatment‑related serious adverse events. Pharvaris plans to use the CHAPTER‑3 data to support regulatory filings and intends to submit a New Drug Application to the FDA in the first half of 2027. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasEn 2022, Pharvaris Aktie ya ha pagado 0,10 € en dividendos. El último pago fue en julio de 2022.
Datos financieros
En el último trimestre, Pharvaris Aktie tuvo unos ingresos de 0 € y un beneficio neto de -47,41 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | 0 | - |
| Beneficio neto | -47,41 M | 27,67 % |
| EBITDA | -49,99 M | 34,33 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 2018,43 M € |
Número de acciones | 70,79 M |
Máximo/mínimo de 52 semanas | 39,42 € - 21,10 € |
| Dividendos | No |
Beta | -2,48 |
Ratio P/E | -10,29 |
Ratio PEG | -2,45 |
Ratio P/B | 7,57 |
Ratio P/S | 0,00 |
Perfil de la empresa
Pharvaris N.V., una empresa biofarmacéutica en fase clínica, se centra en el desarrollo y la comercialización de terapias para enfermedades raras. La compañía desarrolla PHA121, un antagonista de molécula pequeña del receptor B2 de la bradicinina que se encuentra en ensayo clínico de fase II para el tratamiento del angioedema hereditario (AEH). También desarrolla PHVS416, una cápsula blanda de liberación rápida y exposición inmediata bajo demanda para pacientes que sufren ataques agudos de AEH, que se encuentra en ensayo clínico de fase 2; y PHVS719, un comprimido profiláctico de liberación prolongada para pacientes con AEH, que se encuentra en ensayo clínico de fase 1. Opera en los Países Bajos, Suiza y Estados Unidos. La compañía se constituyó en 2015 y tiene su sede en Leiden, Países Bajos.
| Nombre | Pharvaris Aktie |
| CEO | Berndt Modig |
| Sede | Zug,
zh Países Bajos |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 05/02/2021 |
| Empleados | 148 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | PHVS |
Frankfurt | 9EN.F |
Düsseldorf | 9EN.DU |
München | 9EN.MU |